Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

818.93 -10.81 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,266,334
Open 828.00
Bid (Size) 811.11 (1)
Ask (Size) 816.50 (1)
Prev. Close 829.74
Today's Range 816.73 - 833.00
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects. 
Via The Motley Fool
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
The U.S. stock market experienced a setback at the end of October, breaking a five-month winning streak. Are politics to blame? 
Via Benzinga

Performance

YTD
+38.29%
+38.29%
1 Month
-7.52%
-7.52%
3 Month
+5.63%
+5.63%
6 Month
+6.82%
+6.82%
1 Year
+44.23%
+44.23%

More News

Read More
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Via Benzinga
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Eli Lilly Stock Is Sinking Today
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Via MarketBeat
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
Via Benzinga
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Via Benzinga
Eli Lilly CEO David Ricks On Q3 Results: The Underlying Growth Story Is Fantastic
Via Talk Markets
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Via Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Via The Motley Fool
Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's
Via Benzinga
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.